Today, Ocugen announced the completion of dosing in the first cohort of the Phase 1/2 ArMaDa clinical trial for OCU410, a modifier gene therapy candidate being developed for geographic atrophy. For more details, https://t.co/uM0ZJMtU90 #ga#dAMD@macular_org@NeenaHaider
Just to make it official!!!
I am Papa Leo and I have been doing my DD for the past three years!
I like to share it with anyone who is willing to learn.
Thank you for all your support!
#OCUGEN#OCU500#COVAXIN#iNCOVACC